MedTrace Logo

Quinolone Resistance in Bloodstream Isolates of Escherichia Coli

NCT00449735 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 500

Last updated 2018-06-12

No results posted yet for this study

Summary

This proposed study aims to document the risk factors for quinolone resistance in bloodstream isolates of E. coli. Additionally, the adequacy of empiric antibiotic therapy for E. coli bloodstream infections will be assessed. Finally, outcome will be recorded - this is all-cause mortality at 28 days from the time of the first positive blood culture. Hypothesis: Ciprofloxacin resistant strains are associated with admission from nursing home and with prior quinolone use.

Conditions

Sponsors & Collaborators

  • University of Pittsburgh

    lead OTHER

Principal Investigators

  • David L Paterson, MD · University of Pittsburgh

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2007-03-31
Primary Completion
2017-06-30
Completion
2017-06-30

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00449735 on ClinicalTrials.gov